Bolt Biotherapeutics, Inc. financial data

Symbol
BOLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Chesapeake Drive, Redwood City, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Bolt Therapeutics, Inc. (to 5/7/2015)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 546 % -27.4%
Debt-to-equity 39.7 % +24.5%
Return On Equity -61.4 % -31.9%
Return On Assets -44 % -24.5%
Operating Margin -695 % +42.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3M shares +0.83%
Common Stock, Shares, Outstanding 38.3M shares +0.83%
Entity Public Float 32.1M USD -37.5%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.1M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 38.1M shares +1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 11.2M USD +64.6%
Research and Development Expense 63.2M USD -4.32%
General and Administrative Expense 22M USD -1.45%
Operating Income (Loss) -77.6M USD +4.89%
Nonoperating Income (Expense) 11.5M USD +137%
Net Income (Loss) Attributable to Parent -66.2M USD +13.8%
Earnings Per Share, Basic -1.74 USD/shares +14.7%
Earnings Per Share, Diluted -1.74 USD/shares +14.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.2M USD -53.9%
Cash, Cash Equivalents, and Short-term Investments 97.5M USD -37.9%
Assets, Current 76.6M USD -41.4%
Property, Plant and Equipment, Net 4.08M USD -27.3%
Operating Lease, Right-of-Use Asset 17.6M USD -14.9%
Other Assets, Noncurrent 308K USD -69.6%
Assets 124M USD -34.9%
Accounts Payable, Current 2.63M USD -23.5%
Employee-related Liabilities, Current 2.89M USD -19.2%
Contract with Customer, Liability, Current 1.4M USD
Liabilities, Current 17.9M USD +1.6%
Operating Lease, Liability, Noncurrent 15.9M USD -15.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 38.3M USD -21.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -44K USD +80.8%
Retained Earnings (Accumulated Deficit) -396M USD -20%
Stockholders' Equity Attributable to Parent 85.9M USD -39.6%
Liabilities and Equity 124M USD -34.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.8M USD +28.4%
Net Cash Provided by (Used in) Financing Activities 107K USD
Net Cash Provided by (Used in) Investing Activities 10.2M USD -64.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38.3M shares +0.83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.55M USD -217%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.97M USD -46.9%
Deferred Tax Assets, Valuation Allowance 83.7M USD +22.7%
Deferred Tax Assets, Gross 89.7M USD +19.2%
Operating Lease, Liability 18.9M USD -12%
Depreciation 1.9M USD +5.56%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -66M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid 27.1M USD -15%
Property, Plant and Equipment, Gross 10.7M USD +2.85%
Operating Lease, Liability, Current 3M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.48M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.34M USD -11.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.25M USD -21.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.6M USD +3.39%
Deferred Tax Assets, Operating Loss Carryforwards 47.3M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 18.7M USD +35.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.72M USD +3.39%
Operating Lease, Payments 1.2M USD +3.36%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 458K USD -1.93%
Deferred Tax Assets, Net of Valuation Allowance 5.98M USD -15.2%
Share-based Payment Arrangement, Expense 9.52M USD +4.75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%